Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L3Tx, also marketed as Liquid Laser, is an aesthetic dermatological product developed and distributed by Kshipra Health Solutions. It is designed as a non-invasive treatment for skin rejuvenation and the management of hyperpigmentation, including melasma and post-inflammatory hyperpigmentation. The formulation is a synergistic combination of tranexamic acid, glutathione, and vitamin C (ascorbic acid). Tranexamic acid acts by inhibiting the plasminogen/plasmin pathway, thereby reducing melanocyte stimulation. Glutathione and vitamin C function as potent antioxidants and direct inhibitors of tyrosinase, the key enzyme in melanin production. L3Tx is typically used in professional clinical settings via topical application or in conjunction with minimally invasive procedures like microneedling to enhance skin tone and texture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L3Tx.